1. Executive Summary
1.1 Multiple Sclerosis Market Review
1.2 Aims, Scope and Format of the Report
2. Introduction to Multiple Sclerosis
2.1 The Biology of MS
2.2 The Disease
2.2.1 Symptoms of MS
2.2.2 Diagnosis of MS
2.3 Measuring MS
2.3.1 The Kurtzke Expanded Disability Status Scale (EDSS)
2.4 The Different Types of MS
2.4.1 Relapsing-Remitting MS
2.4.2 Secondary Progressive MS
2.4.3 Progressive Relapsing MS
2.4.4 Primary Progressive MS
2.4.5 Other Atypical Presentations
2.5 Causational Factors for MS
2.5.1 Genetic Factors
2.5.2 Infection
2.5.3 Environmental Factors and Less Supported Theories
2.6 World Demographics and Economic Costs of MS
2.7 Treatment Options
2.7.1 Alternative Treatments
2.7.2 Medical Approaches
2.8 Pharmacotherapy
2.8.1 Treatment of Acute Symptomatic Attack
2.8.2 Disease-Modifying Treatments
3. The Global Market for MS Drugs, 2010-2025
3.1 MS Drug Market Analysis
3.1.1 The Impact of Oral MS Products on the MS Market
3.2 Copaxone: Leading Drug in the MS Market in 2009
3.2.1 Copaxone Will Benefit from Label Extension
3.2.2 Will Patent Threats Decrease Copaxone Revenues?
3.3 Avonex
3.3.1 Avonex Market Forecast, 2010-2025
3.3.2 Avonex Faces Competition from Newer MS Drugs
3.4 Rebif
3.4.1 Rebif Sales Forecast, 2010-2015
3.4.2 Rebif Long-Term Forecast, 2015-2025
3.5 Betaferon
3.5.1 How Will Patent Expiry Affect Betaferon Sales, 2010-2015?
3.5.2 Betaferon Long-Term Forecast, 2015-2025
3.6 Tysabri
3.6.1 Will Safety Concerns Affect Tysabri Sales?
3.7 Comparison of the Leading MS Drugs
3.8 Multiple Sclerosis Market Summary
4. MS Drugs: Leading National Markets, 2010-2025
4.1 MS Drugs in Nine Major Markets, 2009
4.2 Leading MS Markets: Sales Forecasts, 2010-2025
4.3 The MS Market in the US – Sales Prospects
4.3.1 US Market Drivers
4.3.2 US Market Restraints
4.4 The MS Market in Germany – Sales Prospects
4.5 The MS Market in Japan – Sales Prospects
4.6 The MS Market in France – Sales Prospects
4.7 The MS Market in Italy – Sales Prospects
4.8 The MS Market in Spain – Sales Prospects
4.9 The MS Market in the UK – Sales Prospects
4.10 The MS Market in China – Sales Prospects
4.11 The MS Market in India – Sales Prospects
5. An Analysis of Factors that Influence the MS Market
5.1 SWOT Analysis of the MS Market, 2010
5.2 Market Drivers
5.3 Market Restraints
5.4 The MS Market Has Opportunities for Continuing Growth
5.5 Oral MS Drugs Will Provide More-Accessible Treatment Options
5.6 Advances in Technology are Likely to Bring Benefits to Patients and the Market
5.7 Comparative Studies
5.8 Important Patient Sub-Populations: Potential for Companies to Increase Market Leverage Through Product Differentiation
5.9 Concerns Over the High Price of Treatments
5.10 Generic MS Drugs: How Great is their Threat?
5.11 Improving Safety and Tolerability of MS Drugs
6. Leading Companies in MS Therapy Development
6.1 Key Companies Delivering MS Therapies
6.2 Biogen Idec Leads the MS Market Currently
6.3 Biogen Idec and Elan Pharmaceuticals
6.4 Teva and Sanofi-Aventis
6.5 Merck KGaA
6.6 Bayer
7. Pipeline Drugs for MS
7.1 MS Pipeline Drugs
7.2 The Potential Treatment Options in MS
7.2.1 Reducing Inflammatory Responses
7.2.2 Managing Autoimmune Responses
7.2.3 Manipulating the Permeability of the Blood-Brain Barrier
7.2.4 Inhibiting Demyelination
7.2.5 Protection Axons from Damage
7.2.6 Encouraging Remyelination
7.3 Drugs that Regulate Immune Response
7.3.1 Fingolimod (FTY720)
7.3.2 Cladribine (Oral Formulation)
7.4 Other Drugs that Manage Immune Activity
7.4.1 Teriflunomide
7.4.2 Laquinimod
7.5 Drugs that Reduce Inflammation
7.5.1 Oral Dimethyl Fumerate
7.6 MS Vaccines
7.6.1 Tovaxin
7.6.2 BHT-3009
7.7 Cannabis-Based Treatment for MS?
7.8 An Oral Drug Revolution in MS Treatment?
7.9 MS Pipeline Shows Short- and Long-Term Potential
7.10 The Future of MS Treatment - Other Potential Therapies
7.10.1 Stem Cell Investigations
7.10.2 Thyroid Hormone
8. Expert Opinion on MS Treatment
8.1 Interview with Dr Karen M. Stockl
8.1.1 Improving Self-Management of MS
8.1.2 The Impact and Benefits of DTM Programmes
8.1.3 Improving Medication Adherence in MS Patients
8.1.4 Impact of Oral MS Medications
8.2 Interview with Dr Johan Luthman
8.2.1 On Understanding the Disease and its Treatments
8.2.2 On Unmet Needs for Treatments
8.2.3 On Current Treatment Options
8.2.4 On Medical Marijuana Use
8.2.5 On Oral Drugs
8.2.6 On Future Treatment Possibilities
8.3 Second Interview with Dr Johan Luthman, Specifically Concerning Stem Cell Potential
8.3.1 On Stem Cell Media Coverage
8.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
8.3.3 On the Treatment of Neurological Disorders
8.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment Strategy and Results
8.3.5 On the Time Frame for Marketable Stem Cell Treatment Options
9. Conclusions
9.1 The MS Market Will See Continued Growth
9.2 Scope for Oral MS Drugs to Enter the Market
9.3 Leading Companies in the MS Market
9.4 Market Drivers
9.5 Market Restraints
9.6 MS Drug Market – Summing Up Prospects
[Inhaltsverzeichnis ausblenden]
